People: Facet Biotech Corporation (FACT.O)

FACT.O on Consolidated Issue listed on NASDAQ Global Market

15.77USD
9 Feb 2010
Price Change (% chg)

$0.31 (+2.01%)
Prev Close
$15.77
Open
--
Day's High
$15.78
Day's Low
$15.54
Volume
57,670
Avg. Vol
171,886
52-wk High
$18.35
52-wk Low
$5.86

view people for:

Summary

Name Age Since Current Position
Hasnain, Faheem 50 2008 President, Chief Executive Officer, Director
Guggenhime, Andrew 40 2008 Chief Financial Officer, Senior Vice President
McCamish, Mark 56 2008 Senior Vice President, Chief Medical Officer
Llana, Ted 45 2009 Senior Vice President - Commercial and Corporate Development
Hora, Maninder 55 2008 Vice President - Product and Quality Operations
Sarena, Francis 38 2008 Vice President, General Counsel, Secretary
Cross, Herbert 37 2008 Principal Accounting Officer, Corpoarte Controller
Goodwin, Bradford 54 2008 Director
Parkinson, David 58 2008 Director
Lyons, Gary 58 2008 Director
Von Emster, Kurt 41 2009 Director
Huh, Hoyoung 39 2009 Director
» Insider Trading

Biographies

Name Description
Hasnain, Faheem Mr. Faheem Hasnain was elected to serve on the Board of Directors of Facet Biotech Corporation in November 2008. He currently serves as President and Chief Executive Officer of the Company. Mr. Hasnain was the President and Chief Executive Officer of PDL, having joined PDL in October 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc. ("Biogen"), most recently as its Executive Vice President, Oncology/Rheumatology Strategic Business Unit. From March 2002 to September 2004, Mr. Hasnain served as President, Oncology Therapeutics Network, at Bristol-Myers Squibb Company. From 2000 to 2002, Mr. Hasnain served as Vice President, Global eBusiness, at GlaxoSmithKline and, from 1988 to 2000, he served in key commercial and entrepreneurial roles within GlaxoSmithKline and its predecessor organizations, spanning global eBusiness, international commercial operations, sales and marketing. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.
Guggenhime, Andrew Mr. Andrew Guggenhime, Senior Vice President and Chief Financial Officer of Facet Biotech Corporation, has served in his current position since December 2008. From April 2006 to December 2008, Mr. Guggenhime served as the Senior Vice President and Chief Financial Officer of PDL. From January 2000 to March 2006, Mr. Guggenhime served at Neoforma, Inc., most recently as Chief Financial Officer. Neoforma was a provider of supply chain management solutions for the healthcare industry before it was acquired by Global Healthcare Exchange, LLC in March 2006. From 1996 until 2000, Mr. Guggenhime was a part of the Healthcare Investment Banking group of Merrill Lynch & Co., most recently as a Vice President, where he specialized in working with healthcare services firms and healthcare Internet companies on a variety of transactions, including mergers and acquisitions, initial public offerings, add-on equity offerings and debt offerings. Prior to joining Merrill Lynch & Co., Mr. Guggenhime worked at Wells Fargo & Company in a number of capacities, most recently as Assistant Vice President in Wells Fargo's Real Estate Capital Markets group. Mr. Guggenhime received his B.A. in International Politics and Economics from Middlebury College and his M.M. from the J.L. Kellogg Graduate School of Management at Northwestern University.
McCamish, Mark Dr. Mark McCamish, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Facet Biotech Corporation, has served in his current position since December 2008. From February 2007 to December 2008, Dr. McCamish served as Senior Vice President and Chief Medical Officer of PDL. From 2003 to February 2007, Dr. McCamish served as Chief Medical Officer and Vice President of Clinical Development for Perlegen Sciences, Inc., a company that analyzes unique genetic variations in clinical trial participants to develop genetically targeted, late-stage therapeutics and diagnostics. From January 1998 to September 2003, Dr. McCamish served at Amgen Inc., most recently as Global Development Leader responsible for the clinical development of Amgen's Aranesp® product in new indications. From 1990 to 1997, he worked as a director at Abbott Laboratories with broad responsibilities that included national and international clinical research, design and development of new products in various therapeutic areas. Dr. McCamish received his Ph.D. at Penn State University, his M.D. from the University of California, Los Angeles, and bachelor's and master's degrees from the University of California, Santa Barbara. Dr. McCamish is Board Certified in Internal Medicine and Nutrition & Metabolism.
Llana, Ted Dr. Ted Llana, Ph.D., Senior Vice President, Commercial and Corporate Development, joined Facet Biotech Corporation in January 2009. From September 2001 to November 2008, Dr. Llana held various positions of increasing responsibility at Biogen, most recently as Vice President, Oncology/Rheumatology Strategic Business Unit. In his most recent role at Biogen, he defined and executed the strategy to grow and progress Biogen's oncology and rheumatology pipelines and managed Biogen's Rituxan® collaboration with Genentech, Inc. Prior to working in the oncology business unit, Dr. Llana headed up corporate strategy at Biogen and led global marketing at Biogen. Dr. Llana's prior business experience includes serving as a partner at Documedics, Inc. and as a Vice President at Covance, Inc. where he provided strategic consulting on product commercialization and marketing in the pharmaceutical, biotechnology and medical device industries. Dr. Llana began his career as a Biologist at the National Cancer Institute. He received his Ph.D. in Cellular Immunology from Cornell University and his MBA from Georgetown.
Hora, Maninder Dr. Maninder Hora, Ph.D., Vice President, Product and Quality Operations, joined Facet Biotech Corporation in December 2008. Dr. Hora has over 25 years of drug development experience in the biopharmaceutical and pharmaceutical industry. From July 2006 to December 2008, Dr. Hora served at PDL most recently as Vice President, Product Operations. From 1986 to 2006, Dr. Hora held positions of increasing responsibility with Chiron Corporation (now Novartis) in Emeryville, California, serving most recently at Chiron as Vice President of Process and Product Development. Dr. Hora served as a key member of various teams that successfully registered eight drugs or vaccines in the U.S. and Europe during his 20-year tenure at Chiron. Dr. Hora has also held positions at Wyeth Pharmaceuticals and GlaxoSmithKline PLC prior to joining Chiron. Dr. Hora completed his Ph.D. in Bioengineering from the Indian Institute of Technology, Delhi, India, and was a Fulbright Scholar at the University of Washington, Seattle prior to joining the industry.
Sarena, Francis Mr. Francis Sarena, Vice President, General Counsel and Secretary of Facet Biotech Corporation, has served in his current position since December 2008. From April 2006 to December 2008, Mr. Sarena held positions of increasing responsibility with PDL most recently as Vice President, General Counsel and Secretary of PDL. Mr. Sarena served as a Corporate Associate at Bingham McCutchen LLP from September 2000 to April 2006 representing clients primarily in merger and acquisition transactions, corporate and securities law matters and equity financing transactions. Mr. Sarena received his J.D. from University of California, Berkeley, Boalt Hall School of Law, and his B.S. in Finance from San Francisco State University.
Cross, Herbert Mr. Herbert Cross, Corporate Controller and Principal Accounting Officer, joined Facet Biotech Corporation in December 2008. Prior to joining the Company, Mr. Cross served as the Corporate Controller and principal accounting officer of PDL, having joined PDL in November 2006. From November 1999 to June 2006, Mr. Cross held positions of increasing responsibility at Neoforma, Inc., most recently as Vice President of Finance, a position he held since February 2001. Neoforma was a provider of supply chain management solutions for the healthcare industry before it was acquired by Global Healthcare Exchange, LLC in March 2006. From August 1994 to November 1999, Mr. Cross was employed by Arthur Andersen LLP, an independent public accounting firm, most recently as a Manager in the Assurance and Business Advisory Services group, during which time Mr. Cross managed the audits of both public and private corporations in the software, technology, retail and manufacturing industries. Mr. Cross is a Certified Public Accountant and received his B.S. in Business Administration, with a dual emphasis in Finance and Accounting, from the Haas School of Business at the University of California at Berkeley.
Goodwin, Bradford Mr. Bradford Goodwin was elected to serve on the Board of Directors of Facet Biotech Corporation in November 2008. Mr. Goodwin is currently the President and Chief Executive Officer of Keren Pharmaceutical, Inc., a private company developing external guide sequences (EGSs) as a method of silencing RNA. From 2001 to 2006, Mr. Goodwin served as Chief Executive Officer and a member of the Board of Directors of Novacea, Inc., a publicly held biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. From 2000 to 2001, Mr. Goodwin served as President, Chief Operating Officer and Founder of Collabra Pharma, a privately held company offering pharmaceutical product licensing and development. From 1987 to 2000, Mr. Goodwin held various positions at Genentech, Inc., including most recently Vice President of Finance. While at Genentech, in addition to his finance responsibilities, he helped structure and negotiate significant product licenses, including the license of Rituxan®, and developed long-range strategic plans. Mr. Goodwin is currently a member of the Board of Directors of Rigel Pharmaceuticals, Inc., a publicly held biotechnology company, and Asplendent, which is a privately held entity. Mr. Goodwin received his B.S. degree from the University of California at Berkeley.
Parkinson, David Dr. David R. Parkinson, M.D. was elected to serve on the Board of Directors of Facet Biotech Corporation in November 2008. Since September 2007, Dr. Parkinson has served as President and Chief Executive Officer of Nodality, Inc. From March 2006 to September 2007, Dr. Parkinson served as Senior Vice President, Oncology Research and Development. From May 2003 to March 2006, Dr. Parkinson served as Vice President, Oncology Development, at Amgen Inc. From January 1997 to May 2003, Dr. Parkinson served as Vice President, Global Oncology Clinical Development, at Novartis. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. Prior to the NCI, Dr. Parkinson held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. Dr. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He currently serves on the National Cancer Policy Forum of the Institute of Medicine and is a member of the FDA's Science Board. Dr. Parkinson also serves on the Board of Directors of the American Association of Cancer Research. Dr. Parkinson received his M.D. degree from the University of Toronto Faculty of Medicine and Hematology/Oncology training at McGill University and New England Medical Center.
Lyons, Gary Mr. Gary Lyons was elected to serve on the Board of Directors of Facet Biotech Corporation in November 2008. Mr. Lyons served as the President and Chief Executive Officer of Neurocrine Biosciences, Inc. ("Neurocrine") from February 1993 to January 2008. Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, including Vice President of Business Development and Vice President of Sales. Mr. Lyons also serves on the Boards of Directors of Rigel Pharmaceuticals, Inc., Vical Incorporated and Neurocrine, each of which is a publicly traded biotechnology company. Mr. Lyons received his B.S. in marine biology from the University of New Hampshire and his M.M. from Northwestern University's J.L. Kellogg Graduate School of Management.
Von Emster, Kurt Mr. Kurt Von Emster was elected to serve on the Board of Directors of Facet Biotech Corporation in February 2009. Since March 2009, Mr. von Emster has served as a Managing Director of venBio LLC, a life sciences advisory group. From November 2000 to February 2009, Mr. von Emster was with MPM Capital serving most recently as a Managing Director of MPM BioEquities and as Portfolio Manager for the MPM BioEquities Fund. From July 1989 to November 2000, he was with the Franklin Templeton Group, most recently as a Vice President and Portfolio Manager. He is currently a member of the board of directors at Somaxon Pharmaceuticals, Inc., a public biotechnology company. He is a Chartered Financial Analyst (CFA) and a member of the Association for Investment Management and Research and of the Security Analysts of San Francisco. Mr. von Emster received his B.S. from the University of California at Santa Barbara.
Huh, Hoyoung Dr. Hoyoung Huh, M.D, Ph.D. is Director of Facet Biotech Corporation. Dr. Huh is currently president and chief executive officer of BiPar Sciences, Inc., a oncology therapeutics company and pioneer in the novel mechanism of DNA-repair inhibition. BiPar has recently been acquired by the global pharmaceutical company, sanofi-aventis, in April of 2009, and remains as a center of innovation within sanofi-aventis. Prior to BiPar, Dr. Huh served at Nektar Therapeutics, Inc., as a member of its board of directors, chief operating officer and head of the PEGylation Business Unit. Dr. Huh has led multiple partnerships with pharmaceutical companies, including Bayer AG, Baxter International Inc., Bristol-Myers Squibb Co., Novartis AG, Pfizer, Inc and Roche Holding Ltd. Dr. Huh is a thought leader and frequent speaker on topics including technology licensing, mergers and acquisitions, and innovative product launches. He was a partner at McKinsey & Company, a global management consulting firm, where he served as a leader in the healthcare and biotechnology practice across U.S., Europe and Asia. He currently serves on the board of directors at BayBio, a biotechnology industry association, Interplast, Inc. and SciDose LLC. Dr. Huh received his Doctorate in Medicine degree from Cornell University, Docotrate in Philosophy in Genetics/Cell Biology from Cornell University/Sloan-Kettering Institute, and his A.B. in Biochemistry from Dartmouth College.

Basic Compensation

Name Fiscal Year Total
Hasnain, Faheem 241,027
Guggenhime, Andrew 1,095,490
McCamish, Mark 950,732
Llana, Ted --
Hora, Maninder 830,514
Sarena, Francis --
Cross, Herbert --
Goodwin, Bradford --
Parkinson, David --
Lyons, Gary --
Von Emster, Kurt --
Huh, Hoyoung --
As Of 30 Dec 2008

Insider Trading

Name Shares Traded Price
BVF PARTNERS L P 25,000 $15.72
BVF PARTNERS L P 17,000 $15.72
BVF PARTNERS L P 60,000 $15.72
BVF PARTNERS L P 9,000 $15.70
BVF PARTNERS L P 12,600 $15.70
BVF PARTNERS L P 30,000 $15.70
BVF PARTNERS L P 20,000 $15.66
BVF PARTNERS L P 29,000 $15.66
BVF PARTNERS L P 69,000 $15.66
CROSS HERBERT C 1,319 $15.68
LLANA TED 2,344 $17.39
CROSS HERBERT C 202 $18.03
HASNAIN FAHEEM 8,937 $17.37
LLANA TED 15,000 $0.00
CROSS HERBERT C 1,379 $16.34
SARENA FRANCIS WILLARD 1,182 $16.34
HUH HOYOUNG 8,333 $0.00
BAUPOST GROUP L L C 100,000 $15.40
BAUPOST GROUP L L C 27,900 $15.49
BAUPOST GROUP L L C 150,000 $15.39
BAUPOST GROUP L L C 10,200 $15.50
BAUPOST GROUP L L C 579,432 $15.43
ROLFE MARK 21,333 $0.00
HASNAIN FAHEEM 27,667 $0.00
GUGGENHIME ANDREW L 15,251 $0.00
» Full list on Insider Trading
view people for: